CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Parathyroid hormone-related protein or ''PTHrP''drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00021827
NCT00021827Phase 2Completed

Pathophysiology of PTH-related Protein in Humans.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·interventional·Posted Aug 6, 2001·Updated Mar 2, 2010

In Brief

A Phase 2 clinical trial evaluating Parathyroid hormone-related protein or ''PTHrP'' for Osteoporosis. Completed, across 1 site.

Detailed Summary

PTH-related protein, or ''PTHrP'', is a hormone which was discovered in 1987. As its name implies, it is closely related to another hormone discovered in the 1920's named parathyroid hormone or ''PTH''. PTH has been shown to be effective in treating osteoporosis in both animals and humans. PTHrP has been shown to be effective in treating osteoporosis in laboratory animals, and there are strong scientific reasons to think that it may be effective in humans as well. However, no human trials with PTHrP in the treatment of osteoporosis have been performed. The studies in this trial are focussed on determining whether PTHrP can indeed increase bone mass in postmenopausal women with osteoporosis, when administered daily by subcutaneous injection for three months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 6, 2001
Enrollment StartJun 1, 1999
Study CompletionDec 1, 2001
TodayJul 2, 2026
Posted 24.9 years ago

Interventions

Parathyroid hormone-related protein or ''PTHrP''drug